An interventional study of a Web-Based Platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders in Cognitive Impairment, Speech Dysfunction and Acquired Brain Injury, sponsored by Liverpool University Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Liverpool University Hospitals NHS Foundation Trust · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Cognitive Dysfunction with a site in United Kingdom — 37 open to participants now, 54 under way, 7 of them phase 3. Cognitive Dysfunction · United Kingdom.
Among the 138 studies in Cognitive Dysfunction with a site in United Kingdom, this one is the 43rd largest by planned enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2024, is one of 51 with no phase, reaches primary completion later than 23 of the 53 other live ones, and was the 130th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →37 of the 138 studies in Cognitive Dysfunction with a site in United Kingdom are open now. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 55+
University of Edinburgh · Sites in United Kingdom
Ages 18+
University of Ulster · Sites in United Kingdom
Ages 50+ · Healthy volunteers
Prima Mente · Sites in United Kingdom
Ages 50+
King's College Hospital NHS Trust · Sites in United Kingdom
Ages 18–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 14 · Phase 4 1
First in 2004; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 70 across the 89 interventional studies, 100 across the 49 observational. Of the 71 that completed or were terminated, 21 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 138 have an industry lead sponsor. The 10 most frequent:
Liverpool University Hospitals NHS Foundation Trust is the lead sponsor of 61 studies on the registry; 13 are open to participants now.
Liverpool University Hospitals NHS Foundation Trust has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
8 of the studies in Cognitive Dysfunction with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06207942Region SkaneStepcare Extended Follow-up Substudy | 2027-01 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT06604104University of EdinburghVisual Frailty in Ageing | 2027-01-11 |
| NCT07466446University of EdinburghPost Intensive Care Accelerometery to Study and Support Recovery Outcomes | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 138 studies in Cognitive Dysfunction with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this feasibility study is to explore rehabilitation outcomes, usability and user experience of a web-based platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders in critical illness and stroke disorders.
The main question it aims to answer is:
" Is it feasible to use a web-based platform for delivering rehabilitation treatment in a large acute National Health Care Organisation"
Participants will undergo therapy sessions prescribed by therapists on a web-based platform instead of the conventional paper-based therapy sessions for their cognitive and speech rehabilitation needs.
The population group will be adult patients admitted to critical care unit and stroke unit and diagnosed to have speech and cognitive impairment.
The intervention is to provide therapy prescribed by therapist through Cognishine, a web-based platform instead of paper-based therapy session.
The primary objective is to assess feasibility of using the Cognishine web-based platform in a large NHS Trust in acute care setting measured by number of completed therapy sessions, per patient days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients will receive standard of care rehabilitation. In addition, patients recruited into the study will use the Cognishine platform for cognitive and/or language rehabilitation
Behavioral: a Web-Based Platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders
The Cognishine platform is a digital (web-based) general health and wellness monitoring platform. It is designed to support health care professionals specialised in rehabilitation of patients with neurological disorders, through a wide range of multi-media based generalised activities across speech, language, social-emotional, and cognition.
To assess the feasibility of using the Cognishine web-based platform in a large NHS Trust in acute care setting.
Total number of completed sessions per patient on the cognishine platform
Time frame: From recruitment until discharge from rehabilitation therapy or discharge from hospital, which ever comes first. Time frames will vary dependent on patient recovery .The anticipated time frame is 1 to 6 months. Maximum follow up is 12 months.
To assess staff and patient experience of using the Cognishine platform during therapy sessions.
Patients \& therapists will be asked to complete the Mobile Health App Usability Questionnaire (MAUQ)for Interactive Mobile Health Apps used by patients. The questionnaire is designed and validated to evaluate the usability of interactive health apps from the users perspective. The MAUQ questionnaire comprises of 21 questions which cover 3 main usability domains. 1. Ease of use-Navigation, learnability and clarity. 2. Interface and satisfaction-Visual appeal, confidence and overall satisfaction. 3. Usefulness-Perceived value and effectiveness in helping users achieve their health goals. Scoring is via a 7 point Likert scale (1 - strongly disagree, 2 - disagree, 3 - somewhat disagree, 4 - neither agree nor disagree, 5 - somewhat agree, 6 -agree, 7 - strongly agree.),with higher scores indicating greater usability and satisfaction.
Time frame: Patients will be asked to complete this on discharge from hospital. Therapists will be asked to complete the questionnaire one month after starting the study (in the middle of recruitment)
To generate qualitative data about how to improve the end user experience for therapist to target barriers to implementation
Focus groups composed of therapists who have used the platform will be asked to provide end user information about using the system. This qualitative data will be used to improve the platform.
Time frame: 12 month into the study.
To generate preliminary data on the rehabilitation progress associated with the use of the Cognishine platform.
The Montreal Cognitive Assessment (MoCA) is a standard clinical measurement tool. The tool comprises assessment of visuospatial/executive functions ,naming, memory, attention, language ,abstraction and orientation. The scoring range is 0-30,with higher scores indicating better cognition, scores of \<26 indicating possible cognitive impairment. Scores will be collected from clinical notes at initial assessment and at discharge from rehabilitation therapy.
Time frame: As recovery is highly individualised time frames will vary amongst participants .It is anticipated that the time frame will range from 1 to 6 months.
To generate preliminary data on the rehabilitation progress associated with the use of the Cognishine platform.
The Oxford Cognitive Screen(OCS) is specifically for stroke patients and reduces visual or language bias. It assesses attention, executive function, memory, language, number processing and praxis. Each domain is scored with results interpreted as impaired or not impaired. Scores from clinical notes will be collected at initial assessment and at discharge from rehabilitation therapy.
Time frame: As recovery is highly individualised time frames will vary amongst participants .It is anticipated that the time frame will range from 1 to 6 months
To generate preliminary data on the rehabilitation progress associated with the use of the Cognishine platform.
The Orientation log(O-Log) score measures orientation, time place and situation. 10 items are measured , with each item scoring 0-3.The scoring range is 0-30,with higher scores reflecting better function. Scores \<25 indicate disorientation. Scores will be collected at initial assessment and at discharge from rehabilitation therapy
Time frame: As recovery is highly individualised time frames will vary amongst participants .It is anticipated that the time frame will range from 1 to 6 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 23 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Liverpool University Hospitals NHS Foundation Trust